Effect of cognitive behavioral therapy on cognitive function in patients with first-episode depressive disorder

doi:10.3969/j.issn.1004-583X.2024.04.004

Abstract

Abstract:

Objective To explore the effect of cognitive behavior therapy (CBT) on cognitive function in patients with first-episode depressive disorder. Methods Sixty-four eligible patients with first-episode depressive disorder hospitalized in Mental Hospital of Yunnan Province from January 2020 to December 2021 were included as study objects. According to the inclusion order, the first 32 cases were as the combined group (CBT plus escitalopram), and the last 32 cases were as the control group (escitalopram alone). Patients' cognitive function was assessed by the Wsiconsin card sorting test (WCST) and the Struse color word test (Stroop). SPSS was used to analyze the differences between the two groups before and after treatment. Results There were no differences in WCST and Stroop scores between groups before treatment (P >0.05). At the end of the 8th week of treatment, the scores of total response (RA), correct response (RC), persistent correct (RP), and persistent error (RPE) in the two groups were significantly improved (P <0.05), and the scores of RC, RP and RPE in the combination group were significantly better than those of the control group (P <0.05). The scores of conflict response, neutral response and interference response were significantly decreased in the two groups, the decreases were more significant in the combined group relative to the control group (P <0.05). Conclusion Cognitive behavioral therapy can improve cognitive function in patients with first-episode depressive disorder.

Key words: cognitive behavioral therapy, depressive disorder, cognitive function

CLC Number:

R749.42

Lu Xiangxiu, Wang Haiming, Zhang Yijie, Qiu Erxian. Effect of cognitive behavioral therapy on cognitive function in patients with first-episode depressive disorder[J]. Clinical Focus, 2024, 39(4): 320-324.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.04.004

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I4/320

Figures/Tables 3

Tab.1 Balance test for patients with depressive disorders

项目	联合组( $n$ =26)	对照组( $n$ =25)	$t$ / $Z$ /χ²值	$P$ 值
性别(例)
男女	12 14	10 15	0.197	0.657
年龄(岁)	41.58±13.72	38.00±12.32	-0.978	0.333
婚姻状态(例)
未婚	8	8
已婚	16	14	0.314	0.855
离异/丧偶	2	3
受教育程度(例)
初中	9	9
高中	10	5	2.791	0.593
大专	3	6
本科	3	4
硕士及以上	1	1
抑郁障碍家族史(例)
无有	17 9	15 10	0.158	0.691
是否吸烟(例)
无有	20 6	17 8	0.510	0.475
是否饮酒(例)
无有	18 8	20 5	0.778	0.378
基线时HAMD总分(分)	30.31±4.02	31.52±4.38	1.031	0.308
8周末艾司西酞普兰的用量(mg/d)	14.62±4.67	15.20±4.20	0.469	0.641

Tab.1 Balance test for patients with depressive disorders

项目	联合组( $n$ =26)	对照组( $n$ =25)	$t$ / $Z$ /χ²值	$P$ 值
性别(例)
男女	12 14	10 15	0.197	0.657
年龄(岁)	41.58±13.72	38.00±12.32	-0.978	0.333
婚姻状态(例)
未婚	8	8
已婚	16	14	0.314	0.855
离异/丧偶	2	3
受教育程度(例)
初中	9	9
高中	10	5	2.791	0.593
大专	3	6
本科	3	4
硕士及以上	1	1
抑郁障碍家族史(例)
无有	17 9	15 10	0.158	0.691
是否吸烟(例)
无有	20 6	17 8	0.510	0.475
是否饮酒(例)
无有	18 8	20 5	0.778	0.378
基线时HAMD总分(分)	30.31±4.02	31.52±4.38	1.031	0.308
8周末艾司西酞普兰的用量(mg/d)	14.62±4.67	15.20±4.20	0.469	0.641

Tab.2 Inter-group comparison of WCST score before and after treatment

组别	例数	RA		RC		RP		RPE
组别	例数	干预前	第8周	干预前	第8周	干预前	第8周	干预前	第8周
联合组	26	91.35±10.37	78.00±7.30^*	42.62±2.38	52.62±5.15^*	12.96±2.65	21.00±2.42^*	34.12±3.20	25.27±4.49^*
对照组	25	86.24±12.92	76.00±8.56^*	43.00±2.55	47.68±4.43^*	14.00±2.99	15.72±3.86^*	34.88±2.71	29.32±4.21^*
$t$ 值		-1.560	-0.899	0.557	-3.660	1.316	-5.883	0.918	3.318
$P$ 值		0.125	0.373	0.580	0.001	0.194	<0.001	0.363	0.002

Tab.2 Inter-group comparison of WCST score before and after treatment

组别	例数	RA		RC		RP		RPE
组别	例数	干预前	第8周	干预前	第8周	干预前	第8周	干预前	第8周
联合组	26	91.35±10.37	78.00±7.30^*	42.62±2.38	52.62±5.15^*	12.96±2.65	21.00±2.42^*	34.12±3.20	25.27±4.49^*
对照组	25	86.24±12.92	76.00±8.56^*	43.00±2.55	47.68±4.43^*	14.00±2.99	15.72±3.86^*	34.88±2.71	29.32±4.21^*
$t$ 值		-1.560	-0.899	0.557	-3.660	1.316	-5.883	0.918	3.318
$P$ 值		0.125	0.373	0.580	0.001	0.194	<0.001	0.363	0.002

Tab.3 Inter-group comparison of Stroop score before and after treatment

组别	例数	冲突反应时		中性反应时		干扰反应时
组别	例数	干预前	第8周	干预前	第8周	干预前	第8周
联合组	26	300.62±25.31	246.00±19.25^*	258.92±19.77	211.69±7.89^*	58.04±7.62	43.65±4.32^*
对照组	25	304.80±24.27	265.68±18.51^*	254.20±15.35	221.88±14.60^*	58.68±7.06	48.84±6.59^*
$t$ 值		0.602	3.720	-0.950	3.117	0.312	3.338
$P$ 值		0.550	0.001	0.347	0.003	0.757	0.002

Tab.3 Inter-group comparison of Stroop score before and after treatment

组别	例数	冲突反应时		中性反应时		干扰反应时
组别	例数	干预前	第8周	干预前	第8周	干预前	第8周
联合组	26	300.62±25.31	246.00±19.25^*	258.92±19.77	211.69±7.89^*	58.04±7.62	43.65±4.32^*
对照组	25	304.80±24.27	265.68±18.51^*	254.20±15.35	221.88±14.60^*	58.68±7.06	48.84±6.59^*
$t$ 值		0.602	3.720	-0.950	3.117	0.312	3.338
$P$ 值		0.550	0.001	0.347	0.003	0.757	0.002

References 20

[1]	王海明, 赵青枫, 方静, 等. proBDNF与抑郁障碍认知功能损害的研究进展[J]. 基层医学论坛, 2022, 26(34):106-109.
[2]	李凌江, 马辛. 中国抑郁障碍防治指南[M]. 2版. 北京: 中华医学电子音像出版社, 2015:87-90.
[3]	Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis[J]. Lancet, 2018, 391(10128):1357-1366. doi: S0140-6736(17)32802-7 pmid: 29477251
[4]	刘强, 李洪超, 马爱霞. 一线抗抑郁药临床疗效的网状Meta分析[J]. 中国药物评价, 2016, 2(33):106-110.
[5]	Beck AT. Cognitive therapy of depression[M]. New York: Guilford Press, 1979:15.
[6]	Fang X, Zhang C, Wu Z, et al. The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder[J]. J Affect Disord, 2019, 245:17-21.
[7]	Rosenberg LI. The ham-D is not Hamilton's depression scale[J]. Psychopharmacol Bull, 2022, 52(2):117-153. pmid: 35721817
[8]	Baron SI. Neuropsychological evaluationofthe child[M]. New York: Oxford University Press, 2004:429-437.
[9]	Bajaj JS, Thacker LR, Heuman DM, et al. The Stroopsmartphone application is a short and valid method to screenfor minimal hepatic encephalopathy[J]. Hepatology, 2013, 58(3):1122-1132.
[10]	段登艾, 邓燕, 张志雄, 等. 辩证行为疗法联合舍曲林对伴有非自杀性自伤的青少年抑郁障碍患者的影响[J]. 临床荟萃, 2023, 38(4):319-323.
[11]	黄薛冰. 焦虑障碍的团体认知行为治疗临床实操手[M]. 北京: 北京大学医学出版社, 2019:139.
[12]	Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: A cross-sectional epidemiological study[J]. Lancet Psychiatry, 2019, 6(3):211-224. doi: S2215-0366(18)30511-X pmid: 30792114
[13]	World Health Organization. The global burden of disease:2004update[R]. Geneva:WHO, 2008.
[14]	储召松, 沈宗霖, 程宇琪, 等. 抑郁症认知功能障碍的脑磁共振成像研究进展[J]. 中国神经精神疾病杂志, 2020, 46(11):693-696.
[15]	王朔, 江涛, 刘托. 音乐治疗联合艾司西酞普兰治疗首发抑郁障碍临床疗效评价[J]. 神经损伤与功能重建, 2021, 16(8):476-477, 496.
[16]	邓雪梅, 许雅楠, 罗渝川, 等. CBT联合SSRIs对青少年抑郁症疗效的元分析[J]. 精神医学杂志, 2022, 35(4):359-364.
[17]	吴素英. 认知行为疗法对强症迫患者执行功能的影响[J]. 齐齐哈尔医学院学报, 2016, 37(26):3329-3331.
[18]	黄尚岗. 认知行为疗法干预治疗老年抑郁症的研究进展[J]. 中国卫生标准管理, 2023, 14(1):195-198.
[19]	Kyle SD, Hurry M, Richard E, et al. The effects of digital cognitivebehavioral therapy for insomnia on cognitive function: A randomizedcontrolled trial[ J]. Sleep, 2020, 43(9):172-180.
[20]	吴怡, 陶红莉. 盐酸舍曲林片联合认知行为疗法治疗青少年抑郁症的疗效及对认知功能、睡眠状况、自杀意念的影响[J]. 海南医学, 2022, 33(21):2776-2779.